|Bid||101.50 x 800|
|Ask||106.30 x 900|
|Day's range||102.75 - 104.52|
|52-week range||52.17 - 107.77|
|PE ratio (TTM)||99.82|
|Earnings date||3 Dec 2018 - 7 Dec 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||98.42|
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.
A relatively unknown company has struck a major deal with Apple, and is now seeking to earn a remarkable $3,750 per square foot per year in what can be seen as a unique real estate play
2018 Veeva R&D Summit -- Veeva Systems (VEEV) today announced a next-generation cloud application to streamline clinical data management and accelerate study execution. Veeva Vault CDMS eliminates the need for multiple tools with a single clinical data management application that combines coding, EDC, data cleaning, and reporting. Companies can now have one application that allows them to manage study build through execution and gain a complete and concurrent view of all clinical data within a trial.
Veeva Systems (VEEV) today announced increasing numbers of medical devices and diagnostics (MD&D) companies are adopting Veeva Vault applications to streamline content and data management in clinical, quality, and commercial. Veeva now has more than 65 medical devices and diagnostics customers using Veeva Vault, including 11 of the world’s top 25 medical devices companies.
Modernizing quality management is becoming a top priority among leading life sciences companies. With this shift underway, an increasing number of organizations are unifying quality processes with Veeva Vault Quality applications from Veeva Systems (VEEV). The number of Vault Quality customers has increased to more than 180, including 10 of the top 20 largest global pharmaceutical companies implementing Veeva Vault QualityDocs in at least one division.
Veeva Systems , a leading industry cloud provider for life sciences, today announced that Tim Cabral, CFO, will present at the Deutsche Bank 2018 Technology Conference on Thursday, September 13, 2018, at 10:00 a.m.
Veeva Systems (VEEV) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Shares of the cloud solutions provider for the life sciences industry continued their upward climb last month. Here's what investors should know.
More than 100 life sciences experts will share best practices to unify processes in clinical, regulatory, and quality
Over the past year, growing numbers of customers are adopting Veeva Vault CTMS to empower clinical teams with one complete source of trial information for faster study execution. Vault CTMS is a next-generation cloud application from Veeva Systems (VEEV) that unifies end-to-end information and processes for greater visibility throughout the trial lifecycle. In 15 months since the product’s availability, 28 sponsors and CROs have selected Vault CTMS and 18 customers are already using the product to streamline clinical operations and improve trial performance.
Veeva Systems (VEEV) today announced the availability of Veeva Vault Submissions Publishing, a new cloud application in the Veeva Vault RIM Suite to unify publishing and submission document authoring. Vault Submissions Publishing automatically publishes and validates documents as they are authored and approved so regulatory teams complete work earlier. Now life sciences organizations can speed submission delivery with seamless traceability, from planning through transmission to the health authority gateway, within a single unified RIM platform.
Veeva Systems (VEEV) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.